Rituximab maintenance therapy in nephrotic syndrome
- Conditions
- Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes
- Registration Number
- CTRI/2022/02/040186
- Lead Sponsor
- Dr Arpita Raychaudhury
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1) Patients with idiopathic nephrotic syndrome with steroid
dependence or frequent relapses who has failed at least one steroid
sparing agent.
2) Secondary steroid resistant nephrotic syndrome with return of steroid sensitivity during treatment of relapse,failing at leat one immunosuppressant other than steroid.
3) In remission state or 24 hr urine protein < 1gm
4) Those who have given informed written consent
1) Primary steroid resistant nephrotic syndrome
2) Secondary cause of nephrotic syndrome
3) Genetic cause of nephrotic syndrome 4) Hepatitis B and C serology positive
5) Acute or chronic active infection
6) Chronic lung disease or uncontrolled asthma
7) Leucopenia or thrombocytopenia
8) ALT/AST >2.5 times upper limit of normal
9) Expected rituximab first infusion date less than 4 weeks from a live
vaccination
10) Regular follow-up not feasible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method